Please assess the completion status of the following clinical trial:

Trial Title: Baclofen for Smoking Cessation in a Non-Psychiatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults (18 years or older).~* Meet DSM-IV criteria for nicotine dependence,~* Smoke ≥10 cigarettes/day,~* Baseline FTND score ≥4, CO level ≥10,~* have had at least one failed quit attempt in the past and are motivated to quit within 30 days of initial intake.~* No previous use of medication for smoking cessation in 1 month prior to randomization.~* BMI between 15 and 40 inclusive.~Exclusion Criteria:~* Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder, or a current or past history of bipolar disorder or schizophrenia~* Have a past history of major depression, with historical evidence of suicidal or homicidal behaviour, or psychotic symptom,~* Have abused alcohol or other drugs of abuse (cocaine, opiates, benzodiazepines, etc) in 3 months prior to randomization~* Demonstrate serious medical conditions, unstable cardiovascular disease, significant blood abnormalities)~* Are pregnant, are trying to become pregnant or are currently breastfeeding~* Baclofen hypersensitivity .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Baclofen 30 mg/day (Type: ACTIVE_COMPARATOR): Baclofen medication
- Placebo pill (Type: PLACEBO_COMPARATOR): placebo pill
- Baclofen 60 mg/day (Type: ACTIVE_COMPARATOR): Baclofen medication high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).